Cargando…
Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521235/ https://www.ncbi.nlm.nih.gov/pubmed/35734931 http://dx.doi.org/10.3324/haematol.2022.281045 |
| _version_ | 1784799798275080192 |
|---|---|
| author | Tefferi, Ayalew Gangat, Naseema Shah, Mithun Alkhateeb, Hassan Patnaik, Mrinal S. Al-Kali, Aref Elliott, Michelle A. Hogan, William J. Litzow, Mark R. Hook, Christopher C. Mangaonkar, Abhishek Viswanatha, David Chen, Dong Pardanani, Animesh Ketterling, Rhett P. Begna, Kebede H. |
| author_facet | Tefferi, Ayalew Gangat, Naseema Shah, Mithun Alkhateeb, Hassan Patnaik, Mrinal S. Al-Kali, Aref Elliott, Michelle A. Hogan, William J. Litzow, Mark R. Hook, Christopher C. Mangaonkar, Abhishek Viswanatha, David Chen, Dong Pardanani, Animesh Ketterling, Rhett P. Begna, Kebede H. |
| author_sort | Tefferi, Ayalew |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9521235 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95212352022-10-24 Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience Tefferi, Ayalew Gangat, Naseema Shah, Mithun Alkhateeb, Hassan Patnaik, Mrinal S. Al-Kali, Aref Elliott, Michelle A. Hogan, William J. Litzow, Mark R. Hook, Christopher C. Mangaonkar, Abhishek Viswanatha, David Chen, Dong Pardanani, Animesh Ketterling, Rhett P. Begna, Kebede H. Haematologica Letter to the Editor Fondazione Ferrata Storti 2022-06-23 /pmc/articles/PMC9521235/ /pubmed/35734931 http://dx.doi.org/10.3324/haematol.2022.281045 Text en Copyright© 2022 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letter to the Editor Tefferi, Ayalew Gangat, Naseema Shah, Mithun Alkhateeb, Hassan Patnaik, Mrinal S. Al-Kali, Aref Elliott, Michelle A. Hogan, William J. Litzow, Mark R. Hook, Christopher C. Mangaonkar, Abhishek Viswanatha, David Chen, Dong Pardanani, Animesh Ketterling, Rhett P. Begna, Kebede H. Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience |
| title | Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience |
| title_full | Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience |
| title_fullStr | Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience |
| title_full_unstemmed | Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience |
| title_short | Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience |
| title_sort | daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the mayo clinic experience |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521235/ https://www.ncbi.nlm.nih.gov/pubmed/35734931 http://dx.doi.org/10.3324/haematol.2022.281045 |
| work_keys_str_mv | AT tefferiayalew daunorubicin60versusdaunorubicin90versusidarubicin12forinductionchemotherapyinacutemyeloidleukemiaaretrospectiveanalysisofthemayoclinicexperience AT gangatnaseema daunorubicin60versusdaunorubicin90versusidarubicin12forinductionchemotherapyinacutemyeloidleukemiaaretrospectiveanalysisofthemayoclinicexperience AT shahmithun daunorubicin60versusdaunorubicin90versusidarubicin12forinductionchemotherapyinacutemyeloidleukemiaaretrospectiveanalysisofthemayoclinicexperience AT alkhateebhassan daunorubicin60versusdaunorubicin90versusidarubicin12forinductionchemotherapyinacutemyeloidleukemiaaretrospectiveanalysisofthemayoclinicexperience AT patnaikmrinals daunorubicin60versusdaunorubicin90versusidarubicin12forinductionchemotherapyinacutemyeloidleukemiaaretrospectiveanalysisofthemayoclinicexperience AT alkaliaref daunorubicin60versusdaunorubicin90versusidarubicin12forinductionchemotherapyinacutemyeloidleukemiaaretrospectiveanalysisofthemayoclinicexperience AT elliottmichellea daunorubicin60versusdaunorubicin90versusidarubicin12forinductionchemotherapyinacutemyeloidleukemiaaretrospectiveanalysisofthemayoclinicexperience AT hoganwilliamj daunorubicin60versusdaunorubicin90versusidarubicin12forinductionchemotherapyinacutemyeloidleukemiaaretrospectiveanalysisofthemayoclinicexperience AT litzowmarkr daunorubicin60versusdaunorubicin90versusidarubicin12forinductionchemotherapyinacutemyeloidleukemiaaretrospectiveanalysisofthemayoclinicexperience AT hookchristopherc daunorubicin60versusdaunorubicin90versusidarubicin12forinductionchemotherapyinacutemyeloidleukemiaaretrospectiveanalysisofthemayoclinicexperience AT mangaonkarabhishek daunorubicin60versusdaunorubicin90versusidarubicin12forinductionchemotherapyinacutemyeloidleukemiaaretrospectiveanalysisofthemayoclinicexperience AT viswanathadavid daunorubicin60versusdaunorubicin90versusidarubicin12forinductionchemotherapyinacutemyeloidleukemiaaretrospectiveanalysisofthemayoclinicexperience AT chendong daunorubicin60versusdaunorubicin90versusidarubicin12forinductionchemotherapyinacutemyeloidleukemiaaretrospectiveanalysisofthemayoclinicexperience AT pardananianimesh daunorubicin60versusdaunorubicin90versusidarubicin12forinductionchemotherapyinacutemyeloidleukemiaaretrospectiveanalysisofthemayoclinicexperience AT ketterlingrhettp daunorubicin60versusdaunorubicin90versusidarubicin12forinductionchemotherapyinacutemyeloidleukemiaaretrospectiveanalysisofthemayoclinicexperience AT begnakebedeh daunorubicin60versusdaunorubicin90versusidarubicin12forinductionchemotherapyinacutemyeloidleukemiaaretrospectiveanalysisofthemayoclinicexperience |